TID Section-ATS COVID-19 Resources

COVID-19 global numbers 

Stay tuned with updated information from CDC, FDA , NIH, and ATS.

How it spreads 

Protect yourself

Guidelines for cloth face masks 

Social distancing

Cleaning and disinfecting your home

COVID-19 resources for healthcare professionals 

Funding opportunities:

BARDA 

NIH

Published literature on COVID-19:

1. Coronavirus disease 2019 (COVID-19): a clinical update.

   Zhou M, Zhang X, Qu J.Zhou M, et al.Front Med. 2020 Apr 2. doi: 10.1007/s11684-020-0767-8. Online ahead of print.Front Med. 2020.PMID: 32240462Review.

2. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up.

   Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H.Wang L, et al.J Infect. 2020 Mar 30. doi: 10.1016/j.jinf.2020.03.019. Online ahead of print.J Infect. 2020.PMID: 32240670Free PMC article.

3. Estimates of the severity of coronavirus disease 2019: a model-based analysis.

   Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM.Verity R, et al.Lancet Infect Dis. 2020 Mar 30:S1473-3099(20)30243-7. doi: 10.1016/S1473-3099(20)30243-7. Online ahead of print.Lancet Infect Dis. 2020.PMID: 32240634

4. Potential therapeutic agents against COVID-19: What we know so far.

   Lu CC, Chen MY, Chang YL.Lu CC, et al.J Chin Med Assoc. 2020 Apr 1. doi: 10.1097/JCMA.0000000000000318. Online ahead of print.J Chin Med Assoc. 2020.PMID: 32243270

5. Nervous system involvement after infection with COVID-19 and other coronaviruses.

   Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C.Wu Y, et al.Brain Behav Immun. 2020 Mar 30:S0889-1591(20)30357-3. doi: 10.1016/j.bbi.2020.03.031. Online ahead of print.Brain Behav Immun. 2020.PMID: 32240762Review.

6. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
   
   Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ.Ahn DG, et al.J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011.J Microbiol Biotechnol. 2020.PMID: 32238757Review.

7. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection.

   Qiu L, Liu X, Xiao M, Xie J, Cao W, Liu Z, Morse A, Xie Y, Li T, Zhu L.Qiu L, et al.Clin Infect Dis. 2020 Apr 2:ciaa375. doi: 10.1093/cid/ciaa375. Online ahead of print.Clin Infect Dis. 2020.PMID: 32241022

8. Routine childhood immunization may protect against COVID-19.

   Salman S, Salem ML.Salman S, et al.Med Hypotheses. 2020 Mar 25;140:109689. doi: 10.1016/j.mehy.2020.109689. Online ahead of print.Med Hypotheses. 2020.PMID: 32240961No abstract available.

9. The epidemiology, diagnosis and treatment of COVID-19.

   Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y.Zhai P, et al.Int J Antimicrob Agents. 2020 Mar 28:105955. doi: 10.1016/j.ijantimicag.2020.105955. Online ahead of print.Int J Antimicrob Agents. 2020.PMID: 32234468

10. Virological assessment of hospitalized patients with COVID-2019.

    Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C.Wölfel R, et al.Nature. 2020 Apr 1. doi: 10.1038/s41586-020-2196-x. Online ahead of print.Nature. 2020.PMID: 32235945

11. Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms.

    Ilias I, Zabuliene L.Ilias I, et al.Med Hypotheses. 2020 Mar 26;139:109699. doi: 10.1016/j.mehy.2020.109699. Online ahead of print.Med Hypotheses. 2020.PMID: 32240876No abstract available.

12. The 3 Steps Needed to End the COVID-19 Pandemic: Bold Public Health Leadership, Rapid Innovations, and Courageous Political Will.

    Guest JL, Del Rio C, Sanchez T.Guest JL, et al.JMIR Public Health Surveill. 2020 Apr 2. doi: 10.2196/19043. Online ahead of print.JMIR Public Health Surveill. 2020.PMID: 32240972

13. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.

    Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S.Zhang B, et al.Chest. 2020 Mar 31:S0012-3692(20)30571-7. doi: 10.1016/j.chest.2020.03.039. Online ahead of print.Chest. 2020.PMID: 32243945

14. Detection of antibodies against SARS-CoV-2 in patients with COVID-19.

    Du Z, Zhu F, Guo F, Yang B, Wang T.Du Z, et al.J Med Virol. 2020 Apr 3. doi: 10.1002/jmv.25820. Online ahead of print.J Med Virol. 2020.PMID: 32243608

15. Why are pregnant women susceptible to COVID-19? An immunological viewpoint.

    Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH.Liu H, et al.J Reprod Immunol. 2020 Mar 19;139:103122. doi: 10.1016/j.jri.2020.103122. Online ahead of print.J Reprod Immunol. 2020.PMID: 32244166Review.

16. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.

    Zhang C, Wu Z, Li JW, Zhao H, Wang GQ.Zhang C, et al.Int J Antimicrob Agents. 2020 Mar 28:105954. doi: 10.1016/j.ijantimicag.2020.105954. Online ahead of print.Int J Antimicrob Agents. 2020.PMID: 32234467Free PMC article.

17. Gargle lavage as a safe and sensitive alternative to swab samples to diagnose COVID-19: a case report in Japan.

    Saito M, Adachi E, Yamayoshi S, Koga M, Iwatsuki-Horimoto K, Kawaoka Y, Yotsuyanagi H.Saito M, et al.Clin Infect Dis. 2020 Apr 2:ciaa377. doi: 10.1093/cid/ciaa377. Online ahead of print.Clin Infect Dis. 2020.PMID: 32241023No abstract available.

18. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.

    Mégarbane B.Mégarbane B.Clin Toxicol (Phila). 2020 Apr 2:1-2. doi: 10.1080/15563650.2020.1748194. Online ahead of print.Clin Toxicol (Phila). 2020.PMID: 32237918No abstract available.

19. COVID-19 in children and altered inflammatory responses.

    Molloy EJ, Bearer CF.Molloy EJ, et al.Pediatr Res. 2020 Apr 3. doi: 10.1038/s41390-020-0881-y. Online ahead of print.Pediatr Res. 2020.PMID: 32244248No abstract available.

20. High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages.
    
    Chen Z, Fan H, Cai J, Li Y, Wu B, Hou Y, Xu S, Zhou F, Liu Y, Xuan W, Hu H, Sun J.Chen Z, et al.Eur J Radiol. 2020 Mar 24;126:108972. doi: 10.1016/j.ejrad.2020.108972. Online ahead of print.Eur J Radiol. 2020.PMID: 32240913Free PMC article.

21. Use of Systemic Immunomodulatory Therapies During the Coronavirus Disease 2019 (COVID-19) Pandemic.
    
    Shah P, Zampella JG.Shah P, et al.J Am Acad Dermatol. 2020 Mar 31:S0190-9622(20)30478-3. doi: 10.1016/j.jaad.2020.03.056. Online ahead of print.J Am Acad Dermatol. 2020.PMID: 32244021No abstract available.

22. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis.

    Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT, Marusic A, Jeroncic A, Carvas Junior N, Pericic TP, Zakarija-Grkovic I, Meirelles Guimarães SM, Luigi Bragazzi N, Bjorklund M, Sofi-Mahmudi A, Altujjar M, Tian M, Arcani DMC, O'Mathúna DP, Marcolino MS.Borges do Nascimento IJ, et al.J Clin Med. 2020 Mar 30;9(4):E941. doi: 10.3390/jcm9040941.J Clin Med. 2020.PMID: 32235486Review.

23. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.

    Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA, Honein MA, Reddy SC, Jernigan JA; Public Health – Seattle & King County; CDC COVID-19 Investigation Team.Kimball A, et al.MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-381. doi: 10.15585/mmwr.mm6913e1.MMWR Morb Mortal Wkly Rep. 2020.PMID: 32240128

24. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.

    Tiberghien P, de Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.Tiberghien P, et al.Vox Sang. 2020 Apr 2. doi: 10.1111/vox.12926. Online ahead of print.Vox Sang. 2020.PMID: 32240545Review.

25. Why the immune system fails to mount an adaptive immune response to a Covid -19 infection.

    Ahmadpoor P, Rostaing L.Ahmadpoor P, et al.Transpl Int. 2020 Apr 1. doi: 10.1111/tri.13611. Online ahead of print.Transpl Int. 2020.PMID: 32236983

26. Safety of Ibuprofen in Patients with COVID-19; Causal or Confounded?

    Sodhi M, Etminan M.Sodhi M, et al.Chest. 2020 Mar 31:S0012-3692(20)30572-9. doi: 10.1016/j.chest.2020.03.040. Online ahead of print.Chest. 2020.PMID: 32243944No abstract available.

27. The emotional impact of COVID-19: from medical staff to common people.

    Montemurro N.Montemurro N.Brain Behav Immun. 2020 Mar 30:S0889-1591(20)30411-6. doi: 10.1016/j.bbi.2020.03.032. Online ahead of print.Brain Behav Immun. 2020.PMID: 32240766No abstract available.

28. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.

    Cao YC, Deng QX, Dai SX.Cao YC, et al.Travel Med Infect Dis. 2020 Apr 2:101647. doi: 10.1016/j.tmaid.2020.101647. Online ahead of print.Travel Med Infect Dis. 2020.PMID: 32247927Review.

29. The versatile heparin in COVID-19.

    Thachil J.Thachil J.J Thromb Haemost. 2020 Apr 2. doi: 10.1111/jth.14821. Online ahead of print.J Thromb Haemost. 2020.PMID: 32239799

30. COVID-19 as an occupational disease.

    Christopher Carlsten, Mridu Gulati, Stella Hines, Cecile Rose, Kenneth Scott, Susan M Tarlo, Kjell Torén, Akshay Sood, Rafael E de la Hoz et al. Am J Ind Med. 2021 Apr;64(4):227-237. doi: 10.1002/ajim.23222. Epub 2021 Jan 24. PMID: 33491195 PMCID: PMC8014565 DOI: 10.1002/ajim.23222